MYO-029 ( DrugBank: MYO-029 )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
113筋ジストロフィー2

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-000622-67-GB
(EUCTR)
03/06/200510/02/2005A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose, Safety Study of MYO-029 Administered to Adult Patients with Becker, Facioscapulohumeral and Limb-Girdle Muscular Dystrophy.A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose, Safety Study of MYO-029 Administered to Adult Patients with Becker, Facioscapulohumeral and Limb-Girdle Muscular Dystrophy. Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Limb-Girdle Muscular Dystrophy.Product Name: MYO-029
INN or Proposed INN: Not Available
Other descriptive name: Recombinant human anti-GDF-8 antibody
Wyeth Research Division of Wyeth Pharmaceuticals Inc.NULLNot Recruiting Female: yes
Male: yes
136 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
2NCT00104078
(ClinicalTrials.gov)
February 200522/2/2005Study Evaluating MYO-029 in Adult Muscular DystrophyBecker Muscular Dystrophy;Facioscapulohumeral Muscular Dystrophy;Limb-Girdle Muscular DystrophyDrug: MYO-029Wyeth is now a wholly owned subsidiary of PfizerNULLCompleted18 YearsN/ABoth108Phase 1/Phase 2United States